Ranibizumab Treatment for Age-Related Macular Degeneretion

The Correlation for Improvement of Visual Acuity and QOL After Ranibizmab Treatment for Age-Related Macular Degeneration Patients

To establish the correlation between visual acuity improvement and QOL measurement after ranibizumab treatment for AMD patients.

Inclusion Criteria:

• Active primary or recurrent subfoveal choroidal neovascularization lesion due to AMD
• Subjects of either gender age 50 years or older
• Visual acuity better than 0.05 decimal( 20/400 Snellen)
• Signed informed consent form

Exclusion Criteria:

• Prior treatment for neovascular AMD in the study eye, for example, PDT or anti-VEGF therapy
• Patients whose lesion site evaluated by FA examination is more than 12DA in subject eye
• Patients with treatment of triamcinolone intravitreal injection within 6 months in subject eye
• Patients with a history of intraocular surgical operation(including cataract)within 3 months in subject eye
• Patients with serious allergic history to such as fluorescein, indocyanine green, iodophors
• The pregnant or lactating woman